Cargando…
In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer’s Disease
Multiple sources of evidence suggest that soluble amyloid β (Aβ)-oligomers are responsible for the development and progression of Alzheimer’s disease (AD). In order to specifically eliminate these toxic Aβ-oligomers, our group has developed a variety of all-d-peptides over the past years. One of the...
Autores principales: | Schemmert, Sarah, Camargo, Luana Cristina, Honold, Dominik, Gering, Ian, Kutzsche, Janine, Willuweit, Antje, Willbold, Dieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234218/ https://www.ncbi.nlm.nih.gov/pubmed/34207233 http://dx.doi.org/10.3390/ijms22126553 |
Ejemplares similares
-
In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease
por: Schartmann, Elena, et al.
Publicado: (2018) -
PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer’s Disease
por: Camargo, Luana Cristina, et al.
Publicado: (2021) -
Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies
por: Altendorf, Tim, et al.
Publicado: (2023) -
Sex-Related Motor Deficits in the Tau-P301L Mouse Model
por: Camargo, Luana Cristina, et al.
Publicado: (2021) -
The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology
por: van Groen, Thomas, et al.
Publicado: (2017)